MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hara, H.
Right arrow Articles by Adachi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hara, H.
Right arrow Articles by Adachi, T.

Vol. 61, Issue 1, 194-200, January 2002

Contribution of Hepatocyte Nuclear Factor-4 to Down-Regulation of CYP2D6 Gene Expression by Nitric Oxide

Hirokazu Hara and Tetsuo Adachi

Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan

Nitric oxide (NO) released under inflammatory and infectious conditions has been implicated in the down-regulation of many cytochrome P450 genes, but its mechanism of action remains unknown. We showed that the expression of the CYP2D6 gene is down-regulated at the transcriptional level by NO in HepG2 cells. The NO donor (±)-N-[(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexene-1-yl]-3-pyridine carboxamide (NOR4) decreased the expression of CYP2D6 mRNA in a concentration-dependent manner. Using a CYP2D6 promoter-luciferase construct, we found that NOR4 and another NO donor, S-nitrosoglutathione (GSNO), reduced the luciferase activity in a concentration-dependent manner. A guanylate-cyclase inhibitor failed to prevent suppression of CYP2D6 promoter activity by GSNO, indicating that the activity of the CYP2D6 promoter is suppressed via an NO-guanylate cyclase-independent pathway. Deletion analysis of the CYP2D6 promoter revealed that the -80 to +65 region, which contains the nuclear receptor hepatocyte nuclear factor-4 (HNF4) binding site, was responsible for the suppression of CYP2D6 promoter activity by NO. Therefore, we examined NO responsiveness of the HNF4 binding site by electrophoretic mobility-shift assays and site-direct mutagenesis. The DNA-binding activity of HNF4 was directly inhibited by NO donors, GSNO, and S-nitroso-N-acetyl-penicillamine in a concentration-dependent manner. Mutation of the HNF4 binding site in the CYP2D6 promoter partially restored the suppression of the promoter activity by NO donors. These results demonstrated that NO down-regulates CYP2D6 gene expression, at least in part, by directly inhibiting HNF4 binding to the CYP2D6 promoter.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C.-M. Lee, B.-Y. Kim, L. Li, and E. T. Morgan
Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins
J. Biol. Chem., January 11, 2008; 283(2): 889 - 898.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P.-Y. Cheng, M. Wang, and E. T. Morgan
Rapid Transcriptional Suppression of Rat Cytochrome P450 Genes by Endotoxin Treatment and Its Inhibition by Curcumin
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1205 - 1212.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. A. McConnachie, B. Phillips, M. Bajpai, D. D. Shen, and R. J. Y. Ho
ONLY TRUNCATED, NOT COMPLETE CYTOCHROME P450 2D6 RNA TRANSCRIPT AND NO DETECTABLE ENZYME ACTIVITY ARE EXPRESSED IN HUMAN LYMPHOCYTES
Drug Metab. Dispos., September 1, 2003; 31(9): 1103 - 1107.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Fan, E. Roy, L. Zhu, T. C. Murphy, M. Kozlowski, M. S. Nanes, and J. Rubin
Nitric Oxide Donors Inhibit Luciferase Expression in a Promoter-independent Fashion
J. Biol. Chem., March 14, 2003; 278(12): 10232 - 10238.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics